Advertisement
Advertisement
AZN
AstraZeneca PLC
189.01
USDSponsored
+5.13
+2.79%
Nov 04, 15:59 UTC -5
Closed
After-Market
187.73
-1.28
-0.68%
AstraZeneca PLC (AZN) Earnings
AZN Earnings Reports
Positive Surprise Ratio
AZN beat 27 of 43 last estimates.
63%
Next Report
Date of Next Report
Feb 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$17.29B
/$2.49
Implied change from Q3 26 (Revenue/ EPS)
+6.65%
/-10.75%
Implied change from Q4 25 (Revenue/ EPS)
+11.51%
/+17.45%
AstraZeneca PLC earnings per share and revenue
On Oct 30, 2026, AZN reported earnings of 2.79 USD per share (EPS) for Q3 26, beating the estimate of 2.66 USD, resulting in a 4.56% surprise. Revenue reached 16.21 billion, compared to an expected 16.52 billion, with a -1.88% difference. The market reacted with a +7.02% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.49 USD, with revenue projected to reach 17.29 billion USD, implying an decrease of -10.75% EPS, and increase of 6.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Revolution Medicines, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$2.46
Actual
-$1.90
Surprise
+22.81%
Cytokinetics Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$1.48
Actual
-$1.37
Surprise
+7.82%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.09
Actual
$0.02
Surprise
+120.51%
Acadia Pharmaceuticals Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.20
Actual
$0.31
Surprise
+54.85%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
Vir Biotechnology, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.76
Actual
-$0.56
Surprise
+25.20%
uniQure N.V.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.94
Actual
-$0.88
Surprise
+6.39%
Nuvation Bio Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.12
Actual
-$0.12
Surprise
+4.15%
Cytek Biosciences, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+29.97%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were AstraZeneca PLC's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, AstraZeneca PLC reported EPS of $2.79, beating estimates by 4.56%, and revenue of $16.21B, -1.88% below expectations.
How did the market react to AstraZeneca PLC's Q3 2026 earnings?
The stock price moved up 7.02%, changed from $174.40 before the earnings release to $186.65 the day after.
When is AstraZeneca PLC expected to report next?
The next earning report is scheduled for Feb 08, 2027.
What are the forecasts for AstraZeneca PLC's next earnings report?
Based on --
analysts, AstraZeneca PLC is expected to report EPS of $2.49 and revenue of $17.29B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.